WALTHAM, Mass., April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other ...
– Second and third FDA Fast Track Designations for CABA-201, following the systemic lupus erythematosus (SLE) and lupus nephritis (LN) designation, providing the opportunity for expedited development ...
Adicet Bio (NASDAQ:ACET) on Wednesday said that the U.S. Food and Drug Administration has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or ...
MIDDLETON, Mass., Sept. 22, 2025 /PRNewswire/ -- MavriX Bio, a clinical-stage biotechnology company focused on the development of transformative genetic therapies for Angelman syndrome (AS), today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results